Stock Market Reviews

Read and share opinions on TRVI (Trevi Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market

Latest News

• Trevi Therapeutics (TRVI): Assessing Valuation After Clinical Program Advances and Cash Runway Extension
  Nov 15, 2025
• Trevi Therapeutics Inc (TRVI) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ...
  Nov 14, 2025
• Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
  Nov 13, 2025
• Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025
  Nov 6, 2025
• Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference
  Nov 4, 2025
• Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting
  Oct 8, 2025
• Trevi Therapeutics (TRVI): Assessing Valuation as RIVER Trial Data Prepares for Major Scientific Debut
  Sep 23, 2025
• Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025
  Sep 18, 2025
• Haduvio Opportunity Positions Trevi (TRVI) for Multibagger Gains, Says Morgan Stanley
  Sep 11, 2025
• Trevi Therapeutics to Participate in Upcoming September Conferences
  Aug 28, 2025
• Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans
  Aug 10, 2025
• Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
  Aug 7, 2025
• Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025
  Jul 31, 2025
• Trevi Therapeutics to Participate in Upcoming August Conferences
  Jul 29, 2025
• Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know
  Jul 11, 2025
• Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism
  Jul 1, 2025
• Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
  Jun 5, 2025